Zingiberen newsaponin
Based on 1 Customer Validation
Zingiberen Newsaponin (Zingiberensis newsaponin) is an orally active type of steroid saponin compound. Zingiberen Newsaponin exerts anti-hepatocellular carcinoma (HCC) effects by inhibiting autophagy and the AKR1C1/JAK2/STAT3 pathway. Zingiberen Newsaponin activates oxidative stress (upregulates ROS and MDA) and mitochondrial pathways, promoting cancer cell apoptosis. Zingiberen Newsaponin alleviates cerebral ischemia-reperfusion (I/R) injury by decreasing the concentration of pro-inflammatory cytokines and inhibits NF-κB. Zingiberen Newsaponin can enhance the activity of SOD, eliminate free radicals and protect nerve cells. Zingiberen Newsaponin induces platelet aggregation.
For research use only. We do not sell to patients.
- Purity: 99.68%
- CAS No.: 91653-50-8
- Formula: C51H82O22
- Molecular Weight:1047.18
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Zingiberen Newsaponin (0-2 μM, 48 h) inhibits proliferation of Huh7 and SMMC-7721 cells, with IC50 values of 443.8 nM and 841.8 nM[2].
Zingiberen Newsaponin (0.5-1 μM, 24-48 h) significantly inhibits the migration of Huh7 and SMMC-7721 cells and induces cell apoptosis[2].
Zingiberen Newsaponin (0.5-1 μM, 48 h) inhibits AKR1C1/JAK2/STAT3 signaling pathway, induces oxidative stress and inhibits autophagy in Huh7 and SMMC-7721 cells[2].
Zingiberen Newsaponin (48 h) significantly reduces the secretion of pro-inflammatory cytokines TNF-α and IL-6 and downregulates NF-κB protein expression in LPS (HY-D1056)-stimulated RAW264.7 cells[3].
Zingiberen Newsaponin (48 h) significantly improves PC12 cell survival and reduces apoptosis in an ischemia-reperfusion (I/R) cell model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Huh7 and SMMC-7721 cells
-
Concentration:0.5 μM (Huh7) and 1 μM (SMMC-7721)
-
Incubation Time:24 h
-
Result:Significantly inhibited the migration of HCC cells.
-
Cell Line:Huh7 and SMMC-7721 cells
-
Concentration:0.5 μM (Huh7) and 1 μM (SMMC-7721)
-
Incubation Time:48 h
-
Result:Significantly promotes HCC cell apoptosis.
-
Cell Line:Huh7 and SMMC-7721 cells
-
Concentration:0.5 μM (Huh7) and 1 μM (SMMC-7721)
-
Incubation Time:48 h
-
Result:Significantly increased ROS, SOD, and MDA levels in HCC cells.
-
Cell Line:Huh7 and SMMC-7721 cells
-
Concentration:0.5 μM (Huh7) and 1 μM (SMMC-7721)
-
Incubation Time:48 h
-
Result:Downregulated AKR1C1, p-JAK2, and p-STAT3 expression.
Zingiberen Newsaponin (i.g., once daily for 7 days or single dose) significantly improves cerebral I/R injury, reducing infarct size and neurological deficits in rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SMMC-7721 xenograft model model established in BALB/c nude mice (4 weeks old, male)[2]
-
Dosage:60 mg/kg
-
Administration:Oral administration (p.o.), once daily for 28 days
-
Result:Significantly inhibited tumor growth, reducing tumor volume and weight.
Decreased Ki67 (a proliferation marker) expression and promoted tumor cell apoptosis.
Chemical Information
-
CAS No. 91653-50-8
-
Appearance Solid
-
Molecular Weight 1047.18
-
Formula C51H82O22
-
Color White to off-white
-
SMILES
C[C@@]12[C@]([C@@H]3C)([H])[C@](O[C@]34CC[C@@H](C)CO4)([H])C[C@@]1([H])[C@@](CC=C5[C@@]6(CC[C@H](O[C@@](O[C@H](CO)[C@@H](O[C@@](O[C@H](CO)[C@@H](O)[C@@H]7O[C@]([C@@H]([C@@H](O)[C@@H]8O)O)([H])O[C@@H]8CO)([H])[C@@H]7O)[C@@H]9O)([H])[C@@H]9O[C@@](O[C@@H](C)[C@H](O)[C@H]%10O)([H])[C@@H]%10O)C5)C)([H])[C@]6([H])CC2
-
Synonyms
Zingiberensis newsaponin
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
DMSO : 100 mg/mL (95.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (2.39 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang JJ, et al. Study on steroidal saponins from Dioscorea zingiberensis and their platelet aggregation activities. Zhongguo Zhong Yao Za Zhi. 2014 Oct;39(19):3782-7. [Content Brief]
[2]. He K, et al. Zingiberensis Newsaponin Inhibits the Malignant Progression of Hepatocellular Carcinoma via Suppressing Autophagy Moderated by the AKR1C1-Mediated JAK2/STAT3 Pathway. Evid Based Complement Alternat Med. 2021 Dec 13;2021:4055209. [Content Brief]
[3]. Xue Z, et al. New steroid saponins from Dioscorea zingiberensis yam and their medicinal use against I/R via anti-inflammatory effect. Food Funct. 2021 Sep 20;12(18):8314-8325. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9549 mL | 4.7747 mL | 9.5495 mL | 23.8736 mL |
| 5 mM | 0.1910 mL | 0.9549 mL | 1.9099 mL | 4.7747 mL | |
| 10 mM | 0.0955 mL | 0.4775 mL | 0.9549 mL | 2.3874 mL | |
| 15 mM | 0.0637 mL | 0.3183 mL | 0.6366 mL | 1.5916 mL | |
| 20 mM | 0.0477 mL | 0.2387 mL | 0.4775 mL | 1.1937 mL | |
| 25 mM | 0.0382 mL | 0.1910 mL | 0.3820 mL | 0.9549 mL | |
| 30 mM | 0.0318 mL | 0.1592 mL | 0.3183 mL | 0.7958 mL | |
| 40 mM | 0.0239 mL | 0.1194 mL | 0.2387 mL | 0.5968 mL | |
| 50 mM | 0.0191 mL | 0.0955 mL | 0.1910 mL | 0.4775 mL | |
| 60 mM | 0.0159 mL | 0.0796 mL | 0.1592 mL | 0.3979 mL | |
| 80 mM | 0.0119 mL | 0.0597 mL | 0.1194 mL | 0.2984 mL |
Zingiberen newsaponin Related Classifications
HY-N2282 Related Classifications
Powered by Bioz